Psychopharmacology. FDA weighs suicide risk in children on antidepressants.
Holden
Constance
C
D000293:Adolescent; D026683:Advisory Committees; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D002648:Child; D018849:Controlled Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy; D006801:Humans; D011358:Product Surveillance, Postmarketing; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D013405:Suicide; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration
D018687:Antidepressive Agents, Second-Generation; D017367:Selective Serotonin Reuptake Inhibitors